Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
November 18, 2015Science Translational MedicineOpen Access

AZD9150, a next-generation antisense oligonucleotide inhibitor of STAT3 with early evidence of clinical activity in lymphoma and lung cancer

View Full Paper
Ask AI
Bookmark
Share

Authors

DHDavid S. HongUniversity of Southern California
Razelle Kurzrock
Razelle KurzrockFroedtert HospitalYKYoungsoo KimIonis Pharmaceuticals (United States)

Discussion

Loading...

Member takes

Implication

Key Points

Key points are not available for this paper at this time.

Cite This Study

Hong et al. (2015) studied this question.

synapsesocial.com/papers/69d7370bf07a12db70b8a5b0https://doi.org/10.1126/scitranslmed.aac5272
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Gefitinib in Combination With Paclitaxel and Carboplatin in Advanced Non–Small-Cell Lung Cancer: A Phase III Trial—INTACT 22004 · 1,720 citations
  2. 2Efficient gene silencing by delivery of locked nucleic acid antisense oligonucleotides, unassisted by transfection reagents2009 · 394 citations
  3. 3Serum interleukin-6 levels correlate with prognosis in diffuse large-cell lymphoma.1995 · 167 citations
  4. 4Randomized Phase II Study of Docetaxel and Prednisone With or Without OGX-011 in Patients With Metastatic Castration-Resistant Prostate Cancer2010 · 237 citations
  5. 5A Phase 1 Dose Escalation, Pharmacokinetic, and Pharmacodynamic Evaluation of eIF-4E Antisense Oligonucleotide LY2275796 in Patients with Advanced Cancer2011 · 134 citations